For over 37 years, HemaCare has continually been a leading provider of customized, high-quality, consistent, and viable human primary cells, blood components, tissues, and apheresis collection services. BioAspect is the North American distributor of HemaCare products. By partnering with HemaCare, BioAspect gives you more choices and more possibilities to get the cells and tissues tailored to fit your specific research needs.
An adult hematopoietic stem/progenitor cell is a multipotent cell that has a potential to differentiate into any cell type of the lymphoid or myeloid cell line. Hematopoietic stem/progenitor cells can be derived from peripheral blood, bone marrow, or cord blood. Adult stem cells are currently under intense investigation for their potential to treat various human diseases including degenerative diseases. Adult stem cells are present in many tissue types and all share these fundamental qualities: 1) self-renewal, 2) multipotency, and 3) regenerative potential. Hematopoietic stem cells (CD34+) are of particular interest, since they are currently the only type of stem cells used to treat specific human diseases.
The CD34 receptor (or Cluster of Differentiation 34) is well known because of its expression on hematopoietic progenitor cells found in the bone marrow and cord blood. CD34+ stem cells are multipotent cells that can be differentiated into any cell type in blood. They are used in clinics as they have been shown to provide long term durable donor-derived host lymphohematopoietic reconstitution. CD34+ cells are isolated using positive immunomagnetic cell separation procedures from mobilized peripheral blood, bone marrow, or umbilical cord blood.
Cells expressing the CD133 (or Prominin-1) receptor are generally known as primitive hematopoietic stem and progenitor cells. They are usually undifferentiated embryonic stem cells. The cells are normally isolated from bone marrow and cord blood, however, they can also be found in other tissues like liver, muscle, prostate, kidney, and neural tissue. CD133+ stem cells are more "primitive" than CD34+ cells: they have higher proliferation activity and can differentiate into CD34+ cells. HemaCare's CD133+ stem cells are isolated from mobilized peripheral blood, bone marrow, or umbilical cord blood using positive immunomagnetic cell separation procedures. On average, the purity of CD133+ cells is higher than 90%; confirmed by flow cytometric analysis.
1. Well-characterized donor pool. We will make sure that the cells and tissues are collected from donors that meet your requirements on:
2. Samples are collected ethically, and under strict quality control. Cells and tissues are collected in HemaCare's owned and operated FDA-registered collection centers. All donors are qualified as per FDA regulations, CGMP/CGTP principles, and protocol requirements, with Institutional Review Board (IRB)-approved informed consent.
3. We can ship the samples cryopreserved or freshly isolated, depending on your needs.
Our catalogue is constantly being updated so if you do not find the product you are looking for, please contact us for more information.